GRI Bio, Inc. (GRI)

NASDAQ: GRI · Real-Time Price · USD

2.880

+0.590 (25.76%)

At close: Sep 4, 2026, 4:00 PM EDT

2.584

-0.296 (-10.28%)

After-hours: Sep 4, 2026, 7:59 PM EDT

Market Cap	6.30M +71.4%
Revenue (ttm)	n/a
Net Income	-9.66M
EPS	-11.55
Shares Out	2.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,464,779
Open	2.340
Previous Close	2.290
Day's Range	2.330 - 3.360
52-Week Range	1.360 - 80.360
Beta	-0.55
Analysts	Strong Buy
Price Target	18.50 (+542.36%)
Earnings Date	Aug 14, 2026

About GRI

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2018

Employees 4

Stock Exchange NASDAQ

Ticker Symbol GRI

Website https://www.gribio.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for GRI stock is "Strong Buy." The 12-month stock price target is $18.5, which is an increase of 542.36% from the latest price.

Price Target

$18.5

(542.36% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

GRI Bio Featured in "Why Now" On-Demand Video Webcast

Video webcast now available here

9 days ago - GlobeNewsWire

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimm...

12 days ago - GlobeNewsWire

Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks

Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asset was trading near $63,000 earlier this week.

Other symbols: AGG ARBK BIL BITQ BLOK BND BNDX

16 days ago - New York Post

GRI Bio Quarterly report: Q2 2026

GRI Bio has published its Q2 2026 quarterly earnings report on August 14, 2026.

22 days ago - Filings

GRI Bio announces U.S. FDA granted ODD to GRI-0621

GRI Bio (GRI) announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis, a progressive, irreve...

2 months ago - TheFly

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity

2 months ago - GlobeNewsWire

GRI Bio granted FDA orphan designation for tazarotene

GRI Bio’s (GRI) tazarotene was granted FDA orphan designation as a treatment of idiopathic pulmonary fibrosis, according to a post to the agency’s website.

2 months ago - TheFly

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: G...

3 months ago - GlobeNewsWire

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities ...

3 months ago - GlobeNewsWire

GRI Bio Quarterly report: Q1 2026

GRI Bio has published its Q1 2026 quarterly earnings report on May 13, 2026.

3 months ago - Filings

GRI Bio Earnings release: Q1 2026

GRI Bio released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.

3 months ago - Filings

GRI Bio receives UAE patent allowance for inflammatory disease treatments

GRI Bio (GRI) announced it has received a Notice of Allowance from the United Arab Emirates Patent Office for a patent application covering novel type 2 diverse NKT cell agonists…

5 months ago - TheFly

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market

5 months ago - GlobeNewsWire

GRI Bio Slides: Corporate presentation

GRI Bio has posted slides in relation to its latest quarterly earnings report, which was published on March 6, 2026.

6 months ago - Filings

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Access the “What This Means” segment here

6 months ago - GlobeNewsWire

GRI Bio Transcript: Corporate Connect Webinar Series

GRI Bio highlighted positive phase 2A results for its lead IPF program, showing safety, biomarker improvements, and potential disease-modifying effects. Plans include advancing to phase 2B and filing an IND for a lupus program, with ongoing partnership discussions.

6 months ago - Transcripts